2024-02-01 2025-01-31 false Capium Accounts Production 1.1 13143947 2024-02-01 2025-01-31 13143947 bus:AbridgedAccounts 2024-02-01 2025-01-31 13143947 bus:FRS102 2024-02-01 2025-01-31 13143947 bus:AuditExemptWithAccountantsReport 2024-02-01 2025-01-31 13143947 bus:SmallCompaniesRegimeForAccounts 2024-02-01 2025-01-31 13143947 bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 13143947 2024-02-01 2025-01-31 13143947 2025-01-31 13143947 bus:RegisteredOffice 2024-02-01 2025-01-31 13143947 core:WithinOneYear 2025-01-31 13143947 core:AfterOneYear 2025-01-31 13143947 1 2024-02-01 2025-01-31 13143947 bus:Director1 2024-02-01 2025-01-31 13143947 bus:Director1 2025-01-31 13143947 bus:Director1 2023-02-01 2024-01-31 13143947 bus:Director2 2024-02-01 2025-01-31 13143947 bus:Director2 2025-01-31 13143947 bus:Director2 2023-02-01 2024-01-31 13143947 bus:Director3 2024-02-01 2025-01-31 13143947 bus:Director3 2025-01-31 13143947 bus:Director3 2023-02-01 2024-01-31 13143947 2023-02-01 13143947 bus:LeadAgentIfApplicable 2024-02-01 2025-01-31 13143947 2023-02-01 2024-01-31 13143947 2024-01-31 13143947 core:WithinOneYear 2024-01-31 13143947 core:AfterOneYear 2024-01-31 13143947 bus:EntityAccountantsOrAuditors 2023-02-01 2024-01-31 13143947 core:NetGoodwill 2024-02-01 2025-01-31 13143947 core:NetGoodwill 2025-01-31 13143947 core:NetGoodwill 2024-01-31 13143947 core:CostValuation core:Non-currentFinancialInstruments 2025-01-31 13143947 core:CostValuation core:Non-currentFinancialInstruments 2024-01-31 13143947 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-01-31 13143947 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-01-31 13143947 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-01-31 13143947 core:Non-currentFinancialInstruments 2025-01-31 13143947 core:Non-currentFinancialInstruments 2024-01-31 13143947 core:ShareCapital 2025-01-31 13143947 core:ShareCapital 2024-01-31 13143947 core:RetainedEarningsAccumulatedLosses 2025-01-31 13143947 core:RetainedEarningsAccumulatedLosses 2024-01-31 13143947 dpl:Item1 2024-02-01 13143947 dpl:Item1 2025-01-31 13143947 dpl:Item1 2023-02-01 13143947 dpl:Item1 2024-01-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 13143947
England and Wales

 

 

 

STEETON PHARMA LIMITED



Abridged Accounts
 


Period of accounts

Start date: 01 February 2024

End date: 31 January 2025

STEETON PHARMA LIMITED
Contents Page
For the year ended 31 January 2025
Accountant’s report
You consider that the company is exempt from an audit for the year ended 31 January 2025 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
Myrtle Gund Ltd
31 January 2025



....................................................

Myrtle Gund Ltd
248 Lockwood Road

Huddersfield
HD1 3TG
16 October 2025
1
 
 		 Notes
 		 2025
£		   2024
£
Fixed assets      
Intangible fixed assets 3 478,546    506,695 
478,546    506,695 
Current assets      
Cash at bank and in hand 1,050    555 
Creditors: amount falling due within one year (1,278)   (1,693)
Net current assets (228)   (1,138)
 
Total assets less current liabilities 478,318    505,557 
Creditors: amount falling due after more than one year (676,664)   (641,929)
Net assets (198,346)   (136,372)
 

Capital and reserves 		     
Called up share capital 99    99 
Profit and loss account (198,445)   (136,471)
Shareholders' funds (198,346)   (136,372)
 


For the year ended 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the board of directors on 16 October 2025 and were signed on its behalf by:


-------------------------------
Gowardhan KOTRA
Director
2
General Information
STEETON PHARMA LIMITED is a private company, limited by shares, registered in England and Wales, registration number 13143947, registration address 16 HALLAM ROAD, MOORGATE ROTHERHAM, S60 3DA.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Intangible assets
Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.
Goodwill
Acquired goodwill is stated at cost less amortisation. Amortisation is calculated on a straight line basis over the estimated expected useful economic life of the goodwill of 20 years.
2.

Average number of employees

Average number of employees during the year was 0 (2024 : 0).
3.

Intangible fixed assets

Cost Goodwill   Total
  £   £
At 01 February 2024 562,995    562,995 
Additions -    - 
Disposals -    - 
At 31 January 2025 562,995    562,995 
Amortisation
At 01 February 2024 56,300    56,300 
Charge for year 28,149    28,149 
On disposals -    - 
At 31 January 2025 84,449    84,449 
Net book values
At 31 January 2025 478,546    478,546 
At 31 January 2024 506,695    506,695 


3